UBS Maintains Neutral on Exelixis, Raises Price Target to $52
UBS analyst Ashwani Verma maintains Exelixis (NASDAQ: EXEL ) with a Neutral and raises the price target from $43 to $52.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.